Puma therapeutics shop
Puma therapeutics shop
Puma therapeutics shop
Puma therapeutics shop
Puma therapeutics shop
Puma therapeutics shop

Puma therapeutics shop

Puma therapeutics shop, Puma Biotechnology Announces Presentation of Findings from a Phase I II Study of Alisertib and Pembrolizumab for Rb Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR NCI EORTC Molecula... shop

$37.00

SKU: 7301401

Colour
  • Puma Biotechnology Inc
  • Puma Biotechnology Announces 10 Million Private Placement Business Wire
  • Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib an Investigational Aurora Kinase A Inhibitor Business Wire
  • Puma Biotechnology Inc. LinkedIn
Out of stock
Personalised:
: ( x )
Personalisation:
Edit
Remove Personalisation
Frasers Plus

Buy now.

Pay later.

Earn rewards

Representative APR: 29.9% (variable)

Credit subject to status. Terms apply.

Missed payments may affect your credit score

FrasersPlus